Blog
Three Reasons Why is Insulin STILL So Expensive
29 Aug 2023, 4:49 p.m. in #insulin4all USA by Shaina Kasper
Over the past few months, many insulin manufacturers and other entities have announced that they will be lowering the price of insulin in the United States. So, why is insulin still so expensive?
We recently released our Policy Playbook that goes through all of the details and gives advocates the information to push for change locally and nationally. Why insulin is so expensive can be boiled down to three main points. Read more
Global Advocacy Success Series: Mohammed, Palestine
8 Aug 2023, 9:07 a.m. in Global Stories by Faith Amasowomwan
Mohammed Seyam has been leading T1International's Middle East and North Africa (MENA) Region Chapter since 2021 but has been advocating for himself and his community for much longer. As a medical doctor with type 1 diabetes, he is on a mission to break down barriers to healthcare and education. Mohammed has always been motivated by his community and uses his lived experience to influence his work. Read more
Insulin Pens now on WHO EML: Honoring the Preferences of People with Diabetes
28 Jul 2023, 1:28 p.m. in News & Statements by T1International
We are pleased to announce that the 2023 WHO EML, released yesterday, now includes disposable and reusable pens with cartridges for human insulin. You may remember that two years ago, T1International’s advocacy was instrumental in the WHO’s decision to add long-acting insulin analogues in vials and pens to its EML. This week’s decision paves the way for short-acting insulin analogues to be added to the WHO EML in 2025 in both vial and pen preparations. Read more
Eli Lilly: We Can't Find the $25 Insulin
23 Jun 2023, 10 a.m. in #insulin4all USA, News & Statements by Kate Pidwerbecki
On March 1, Eli Lilly announced it would reduce the list prices of some of its insulins, including the generic Lispro, the same product as the name-brand Humalog. At a recent congressional hearing with the CEOs of insulin manufacturers and pharmacy benefit managers, David Ricks, Eli Lilly’s CEO, again celebrated that $25 insulin lispro was available to patients as of May 1. People with diabetes have worked tirelessly to reduce insulin costs for decades. So why aren’t we universally celebrating this announcement of lower prices? Because it is now the end of May, and I - and many others in my community - still haven’t been able to get the promised $25 insulin.
Read more
Patient Power Shines on US Federal and Global Stages
15 May 2023, 9:29 a.m. in #insulin4all USA, Global Stories, News & Statements by T1International
Advocates recently gathered in Washington, DC to attend the Senate HELP Committee Hearing entitled: The Need to Make Insulin Affordable for All Americans. The hearing, led by Chairman Senator Bernie Sanders, is the culmination of a decade of advocacy efforts by the #insulin4all community who have demanded public accountability for the global insulin price crisis. Read more
Global Advocacy Success Series: Pilar, Panama
4 Apr 2023, 12:10 p.m. in Global Stories, Interviews by Faith Amasowomwan
In 2017, our Global Partner Representative, Pilar moved from the UK to Panama and discovered a stark difference in reality when it came to healthcare. Pilar realised that diabetes care and education within Panama was nowhere near as accessible as it was in the UK and that this was leading to inadequate care for patients, particularly children.
Read more
T1International and #insulin4all Advocates Score Major Win
1 Mar 2023, 11:43 a.m. in #insulin4all USA, Global Stories, News & Statements by T1International
Following years of advocacy on affordable insulin for T1International, today Eli Lilly announced that vials of generic insulin Lispro will be available to all US customers for $25 effective May 1, 2023. Some other Eli Lilly insulins will also be made more affordable by the end of the year. Current list prices for insulin can be over $300 per vial. Read more
T1International Patients Speak out about US Patent Process
20 Feb 2023, 4:47 p.m. in #insulin4all USA, News & Statements by T1International
Patents are intended to provide an exclusive right for a novel invention. By granting a protected property right to an inventor, patents are intended to spur innovation because the patent holder can make significant money for a limited time in exchange for publishing and disclosing the invention. However, the patent system has been exploited by Big Pharma to keep charging high prices on old insulins, or only changing their products in small ways. Read more
Diabetes burnout: a common but neglected impact of diabetes
9 Jan 2023, 6:46 p.m. in #insulin4all USA, Global Stories, News & Statements by Konstantina Taki, Ian Devaney
Research conducted by T1International finds that people living with diabetes are experiencing diabetes burnout at a very high rate, with a significant impact on their health and wellbeing. Read more
T1I’s Top 14 of 2022: A Year in Review
19 Dec 2022, 9:34 a.m. in #insulin4all USA, News & Statements by T1International
With many successes and key moments to reflect on, it is nearly impossible to recap all in a single post. Instead, you can hear favorite moments directly from the 14 members of the T1International team! Read more